A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
| Autor: | Xiaowu Liu, Xue Hu, Chunyin Gu, Zhiming Yuan, Xin Chen, Li Yu, Wuxiang Guan, Li Gao, Nan Li, Zhongzong Pan, Tianquan Hou, Su Jun Deng, Hong Liang, Congyi Yang, Xueyi Huang, Meng Shi, Fangfang Jia, Lu Yang, Yun Peng, Ge Gao, Kunpeng Liu, Donglin Song, Weiwei Guo, Zhen Chen, Chao Shan, Haixia Ma, Guoping Jiang, Yiwu Zhou, Zongda Wang, Xueping Wang, Jianjian Zhang, Yanan Li, Peipei Liu, Zheng Xiao, Yecheng Zhang, Juan Min, Guoqiao Lu, Xiaodan Cao, Yuting Wang, Yanfeng Yao, Weichen Liang, Kaiwen Xia, Jianhua Xue, Haibing Guo, Xiao Hu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
viruses
B.1.351 JMB2002 medicine.disease_cause Epitope Neutralization Epitopes 0302 clinical medicine Antibody Specificity Chlorocebus aethiops Immunology and Allergy Medicine broad-spectrum Neutralizing antibody Coronavirus 0303 health sciences biology neutralizing antibody D614G Rhesus macaque 030220 oncology & carcinogenesis Angiotensin-Converting Enzyme 2 Antibody rhesus macaque disease model Immunology CHO Cells Antiviral Agents Virus 03 medical and health sciences Cricetulus Report Animals phage-to-yeast B.1.1.7 Vero Cells 030304 developmental biology business.industry SARS-CoV-2 COVID-19 biology.organism_classification Virology Antibodies Neutralizing Macaca mulatta COVID-19 Drug Treatment Disease Models Animal biology.protein Vero cell Binding Sites Antibody business Reports |
| Zdroj: | mAbs article-version (VoR) Version of Record |
| ISSN: | 1942-0870 |
| Popis: | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|